Unknown

Dataset Information

0

Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO study.

ABSTRACT:

SUBMITTER: Higue J 

PROVIDER: S-EPMC12371059 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study.
| S-EPMC11347360 | biostudies-literature
Unknown Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML.
| S-EPMC11416634 | biostudies-literature
Unknown Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML.
| S-EPMC12423340 | biostudies-literature
Unknown Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML.
| S-EPMC10788851 | biostudies-literature
Unknown Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.
| S-EPMC10653009 | biostudies-literature
Unknown Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.
| S-EPMC10154410 | biostudies-literature
Unknown Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.
| S-EPMC9242001 | biostudies-literature
Unknown The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy.
| S-EPMC12824654 | biostudies-literature
Unknown Myeloid neoplasm occurrence during stable molecular remission of NPM1-mutated AML: are we facing secondary disease or AML relapse?
| S-EPMC10739830 | biostudies-literature
Unknown Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy.
| S-EPMC9305088 | biostudies-literature